Positive Cancer Trial Results Offset a COVID-19 Flop for Regeneron and Sanofi

Monday was an awfully big day for Regeneron (NASDAQ: REGN) and its collaboration partner, Sanofi (NASDAQ: SNY). The biopharmaceuticals reported successful results from a clinical trial with lung cancer patients, and negative results from a different study with COVID-19 patients.

Preliminary results from a clinical trial of Kevzara in severe-to-critical COVID-19 patients were not quite what the companies had hoped for.

Kevzara, a rheumatoid arthritis treatment, dials down the immune system, which is usually a terrible idea for patients trying to fight off an infection. But in some people, COVID-19 can whip the immune system into a lethal frenzy -- a response called a cytokine storm. Last month, studies were initiated to see whether Kevzara could provide those patients with a survival benefit.

Source Fool.com